Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03013985 · ClinicalTrials.gov registry record · Phase 4
Glargine U300 Hospital Trial
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 247
- Enrollment target
NCT03013985: Completed Phase 4 study, sponsored by Emory University.
NCT03013985 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 247 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03013985, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 247 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if treatment with Glargine U300 when compared to Glargine U100 will result in similar sugar control in patients with Type 2 Diabetes (T2D), who are admitted to the hospital and then transition at home, after discharge from the hospital.
Primary Outcome
The mean daily blood glucose concentration for all participants will be calculated by taking the average of all pre-meal and bedtime glucose values collected each day after the first day of therapy during the hospital stay.
Interventions
- DRUG Glargine U300
- DRUG Glargine U100
- DRUG Glulisine Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2017-05-17 |
| Est. Completion | 2019-03-22 |
| Phase | Phase 4 |
What the finished NCT03013985 record still lists
NCT03013985 is an interventional study that assigns participants to a tested intervention. The registered 247 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 3 interventions - of which Glargine U300 is the first listed.
NCT03013985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03013985 about?
NCT03013985 is a clinical study titled "Glargine U300 Hospital Trial". The purpose of this study is to find out if treatment with Glargine U300 when compared to Glargine U100 will result in similar sugar control in patients with Type 2 Diabetes (T2D), who are admitted to the hospital and then transition at home, after discharge from the hospital.
What is the current status of trial NCT03013985?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 247 participants. The study started on 2017-05-17. Estimated completion is 2019-03-22.
What interventions are being tested in trial NCT03013985?
The interventions under investigation include: Glargine U300 (DRUG), Glargine U100 (DRUG), Glulisine Insulin (DRUG).
Who is sponsoring clinical trial NCT03013985?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03013985's enrollment target sits among peer trials
247 355th of 2000 higher than 1,645 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- NCT04989803 · 247 participants · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- NCT05521399 · 247 participants
Heart Transplantation - Renewal
- NCT05556824 · 247 participants · Phase 2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI